Oppenheimer set a $80.00 price target on Portola Pharmaceuticals (NASDAQ:PTLA) in a research report released on Wednesday. The firm currently has a buy rating on the biopharmaceutical company’s stock. Oppenheimer also issued estimates for Portola Pharmaceuticals’ FY2020 earnings at $3.47 EPS.

Several other research analysts also recently weighed in on the company. Morgan Stanley restated an overweight rating and issued a $81.00 price target (up from $75.00) on shares of Portola Pharmaceuticals in a research note on Friday, October 6th. Credit Suisse Group upgraded Portola Pharmaceuticals from a neutral rating to an outperform rating and set a $70.00 price target for the company in a research note on Wednesday, August 23rd. Goldman Sachs Group started coverage on Portola Pharmaceuticals in a research note on Friday, December 1st. They issued a buy rating and a $75.00 price target for the company. Finally, BidaskClub downgraded Portola Pharmaceuticals from a sell rating to a strong sell rating in a research note on Thursday, December 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $71.15.

Portola Pharmaceuticals (NASDAQ:PTLA) opened at $47.02 on Wednesday. Portola Pharmaceuticals has a 52 week low of $18.30 and a 52 week high of $67.10. The company has a current ratio of 8.31, a quick ratio of 8.31 and a debt-to-equity ratio of 0.24.

Portola Pharmaceuticals (NASDAQ:PTLA) last posted its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.49) by $0.08. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. The business had revenue of $3.83 million during the quarter, compared to the consensus estimate of $4.71 million. During the same period in the prior year, the company posted ($1.64) EPS. The firm’s revenue for the quarter was down 58.9% compared to the same quarter last year. research analysts predict that Portola Pharmaceuticals will post -4.94 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Portola Pharmaceuticals by 14.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,078 shares of the biopharmaceutical company’s stock valued at $117,000 after acquiring an additional 258 shares during the last quarter. Jacobi Capital Management LLC bought a new position in shares of Portola Pharmaceuticals during the 2nd quarter valued at approximately $125,000. IFP Advisors Inc boosted its position in shares of Portola Pharmaceuticals by 7.7% during the 2nd quarter. IFP Advisors Inc now owns 2,370 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 170 shares during the last quarter. QS Investors LLC bought a new position in shares of Portola Pharmaceuticals during the 2nd quarter valued at approximately $147,000. Finally, Oppenheimer Asset Management Inc. boosted its position in shares of Portola Pharmaceuticals by 251.2% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 2,862 shares of the biopharmaceutical company’s stock valued at $155,000 after acquiring an additional 2,047 shares during the last quarter. Hedge funds and other institutional investors own 87.45% of the company’s stock.

WARNING: “Portola Pharmaceuticals (PTLA) Given a $80.00 Price Target at Oppenheimer” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.watchlistnews.com/portola-pharmaceuticals-ptla-given-a-80-00-price-target-at-oppenheimer/1769555.html.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Analyst Recommendations for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.